MARK2 and liver cancer: Sorafenib is the earliest targeted drug approved by the FDA to treat advanced liver cancer and is a multi-target receptor tyrosine kinase inhibitor, which targets to inhibit serine/threonine kinases and other signaling pathways, inhibits the proliferation of a variety of tumor cells and promotes apoptosis.